-
- -First domestic partnership with Tempus AI, the world’s largest holder of clinical and genomic data
-Utilizing patient-derived organoids and real-world data to evaluate drug candidates and develop optimized precision oncology therapies
October 2024
JW Pharmaceutical announced on the 29th that it has partnered with Tempus AI, a global leader in AI-based precision medicine, to accelerate the development of anti-cancer drugs utilizing Real-World Data (RWD) and patient-derived organoids.
This collaboration focuses on swiftly verifying the efficacy and safety of oncology drug candidates while enhancing research efficiency across multiple cancer indications.
JW Pharmaceutical plans to leverage Tempus AI's multimodal datasets, including clinical records and pathology images, in combination with patient-derived organoid models. This approach will enable the precise evaluation of JW’s drug candidates and the validation of biomarkers that predict treatment response.
Tempus AI provides diverse patient-derived organoid models that reflect the unique characteristics of tumors from actual cancer patients. These models are seamlessly integrated with Tempus’s next-generation genomic sequencing technology, xT, and its extensive clinical datasets.
By comparing organoid research results with real patient data, the two companies aim to improve the predictive accuracy of clinical trial outcomes, ultimately developing optimized precision cancer therapies.
Ryan Fukushima, Chief Operating Officer (COO) of Tempus AI, stated, “We are thrilled to partner with JW Pharmaceutical, a company leading next-generation oncology drug development using RWD and AI. Tempus AI has developed organoid panels tailored to specific cancer indications that reflect real patient characteristics. We are eager to see the significant results this research will achieve.”
Chan-hee Park, Chief Technology Officer (CTO) of JW Pharmaceutical, added, “We are excited to establish this first-of-its-kind partnership in Korea with Tempus AI, a global leader in AI and precision medicine. This collaboration marks a significant turning point for real-world data-driven drug development in Korea and is expected to positively impact the domestic pharmaceutical industry by aligning with global trends.”
About Tempus AI
Tempus AI (Nasdaq: TEM) is a technology company advancing precision medicine through the application of artificial intelligence. It houses the world’s largest multimodal data library and provides personalized medical solutions through efficient operational systems. Tempus AI equips physicians with AI-based precision medicine tools, enabling personalized treatment, while supporting the discovery, development, and delivery of optimal therapeutics. Tempus AI’s mission is to help physicians deliver more effective treatments by leveraging its vast data resources.
Tempus AI Press Release URL:https://www.tempus.com/news/tempus-announces-collaboration-with-jw-pharmaceutical-to-apply-real-world-data-and-biological-modeling-to-enhance-early-research-and-development/